|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4844893A
(en)
|
1986-10-07 |
1989-07-04 |
Scripps Clinic And Research Foundation |
EX vivo effector cell activation for target cell killing
|
|
US4980289A
(en)
|
1987-04-27 |
1990-12-25 |
Wisconsin Alumni Research Foundation |
Promoter deficient retroviral vector
|
|
US4873316A
(en)
|
1987-06-23 |
1989-10-10 |
Biogen, Inc. |
Isolation of exogenous recombinant proteins from the milk of transgenic mammals
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US5124263A
(en)
|
1989-01-12 |
1992-06-23 |
Wisconsin Alumni Research Foundation |
Recombination resistant retroviral helper cell and products produced thereby
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
KR100246529B1
(ko)
|
1990-12-14 |
2000-04-01 |
스티븐 에이. 서윈. 엠.디. |
수용체 관련된 신호 변환 경로를 위한 키메라 사슬
|
|
WO1992017198A1
(en)
|
1991-03-28 |
1992-10-15 |
The Regents Of The University Of Minnesota |
Dna and amino acid sequence specific for natural killer cells
|
|
WO1994026290A1
(en)
|
1993-05-07 |
1994-11-24 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
|
CA2168202A1
(en)
|
1993-07-30 |
1995-03-16 |
Joseph Dougherty |
Efficient gene transfer into primary lymphocytes
|
|
US5653977A
(en)
|
1993-09-09 |
1997-08-05 |
Uab Research Foundation |
Anti-idiotypic antibody that mimics the GD2 antigen
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
DE19520729A1
(de)
|
1995-06-07 |
1996-12-12 |
Orpegen Pharma Gmbh |
Testsystem zur Erfassung der Aktivität von NK-Zellen
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US7070771B1
(en)
|
1996-12-09 |
2006-07-04 |
Regents Of The University Of California |
Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
|
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
PT1003861E
(pt)
|
1997-08-01 |
2007-01-31 |
Schering Corp |
Proteínas de membrana de células de mamíferos;reagentes relacionados
|
|
GB9725764D0
(en)
|
1997-12-04 |
1998-02-04 |
Isis Innovation |
HLA-E binding
|
|
KR20010074426A
(ko)
|
1998-02-02 |
2001-08-04 |
추후제출 |
만능 면역조절 사이토킨-발현 방관자 세포주 및 관련조성물 및 제조방법 및 사용방법
|
|
DE19813759C1
(de)
|
1998-03-27 |
1999-07-15 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
EP1104455A2
(en)
|
1998-06-25 |
2001-06-06 |
Hemosol Inc. |
Media and methods for expansion of erythroid stem cells for the production of hemoglobin
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
US7052906B1
(en)
|
1999-04-16 |
2006-05-30 |
Celltech R & D Limited |
Synthetic transmembrane components
|
|
WO2001029191A1
(fr)
|
1999-10-21 |
2001-04-26 |
Keisuke Teshigawara |
Methode de culture in vitro de lymphocytes et compositions de therapie genique
|
|
JP3619853B2
(ja)
|
1999-11-26 |
2005-02-16 |
独立行政法人理化学研究所 |
ナチュラルキラー細胞の増殖方法
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2002045174A
(ja)
|
2000-07-31 |
2002-02-12 |
Inst Of Physical & Chemical Res |
ナチュラルキラー細胞増殖法
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
JP5312721B2
(ja)
|
2000-11-07 |
2013-10-09 |
シティ・オブ・ホープ |
Ｃｄ１９特異的再指向免疫細胞
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20030129649A1
(en)
|
2001-04-24 |
2003-07-10 |
Kobilka Brian K. |
Conformational assays to detect binding to G protein-coupled receptors
|
|
CN101633907B
(zh)
|
2001-08-15 |
2012-09-05 |
宝生物工程株式会社 |
抗原特异性细胞毒性t细胞的扩大培养方法
|
|
CA2457143A1
(en)
*
|
2001-08-17 |
2003-02-27 |
Roger Williams Hospital |
In situ immunization
|
|
US7670781B2
(en)
|
2002-01-03 |
2010-03-02 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
|
|
US7771718B2
(en)
|
2002-04-22 |
2010-08-10 |
Fred Hutchinson Cancer Research Center |
Soluble MIC polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003270823A1
(en)
|
2002-09-19 |
2004-04-08 |
Johns Hopkins University School Of Medicine |
Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
|
|
GB0225279D0
(en)
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
|
US9068234B2
(en)
|
2003-01-21 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating gene expression
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
EP1639001A1
(en)
|
2003-06-27 |
2006-03-29 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050113564A1
(en)
*
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
WO2006023148A2
(en)
|
2004-07-10 |
2006-03-02 |
Fox Chase Cancer Center |
Genetically modified human natural killer cell lines
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
GB0426903D0
(en)
|
2004-12-08 |
2005-01-12 |
Alexis Biotech Ltd |
Complexes and methods
|
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
JP2009513608A
(ja)
|
2005-10-28 |
2009-04-02 |
ノボ・ノルデイスク・エー／エス |
エフェクターリンパ球と標的細胞とを結合する融合タンパク質
|
|
US20070160578A1
(en)
|
2005-12-14 |
2007-07-12 |
The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services |
Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
|
|
ES2385754T3
(es)
|
2006-06-22 |
2012-07-31 |
Novo Nordisk A/S |
Receptores heterodiméricos solubles y usos de estos
|
|
JP5840837B2
(ja)
|
2007-03-30 |
2016-01-06 |
メモリアル スローン−ケタリング キャンサー センター |
養子移入ｔリンパ球における副刺激リガンドの構成性発現
|
|
US20110059137A1
(en)
|
2008-03-21 |
2011-03-10 |
H. Lee Moffitt Cancer Center And Research Institutute, Inc |
Chemokine gene-modified cells for cancer immunotherapy
|
|
WO2010025177A1
(en)
|
2008-08-26 |
2010-03-04 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
CN101684456A
(zh)
|
2008-09-28 |
2010-03-31 |
江门罗森生物制药有限公司 |
一种体外培养条件下扩增人nk细胞的方法
|
|
WO2010071836A1
(en)
|
2008-12-19 |
2010-06-24 |
Inserm |
Il-15 mediated nk and t cell maturation
|
|
EP2410502A4
(en)
|
2009-03-20 |
2015-01-14 |
Ebm Corp |
BLOOD VESSEL MODEL FOR MEDICAL TRAINING AND METHOD FOR MANUFACTURING THE SAME
|
|
CN102428173B
(zh)
|
2009-03-26 |
2014-07-30 |
细胞维护北欧制药公司 |
Nk细胞的扩增
|
|
EP3135294B1
(en)
|
2009-08-14 |
2020-06-03 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Use of il-15-il-15 receptor heterodimers to treat lymphopenia
|
|
WO2011053321A1
(en)
|
2009-10-30 |
2011-05-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells for treatment of multiple myeloma
|
|
EP2493486A1
(en)
|
2009-10-30 |
2012-09-05 |
University Of Arkansas For Medical Science |
Use of autologous effector cells and antibodies for treatment of multiple myeloma
|
|
AU2010325969B2
(en)
|
2009-12-02 |
2016-10-20 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
|
|
ES2851601T3
(es)
|
2009-12-29 |
2021-09-08 |
Gamida Cell Ltd |
Métodos para mejorar la proliferación y actividad de los linfocitos citolíticos naturales
|
|
JP5916718B2
(ja)
|
2010-06-04 |
2016-05-11 |
ビオメリューＢｉｏｍｅｒｉｅｕｘ |
結腸直腸癌の予後判定のための方法及びキット
|
|
KR20230096132A
(ko)
|
2010-07-13 |
2023-06-29 |
셀룰래리티 인코포레이티드 |
천연 킬러 세포의 생성 방법
|
|
ES2754394T3
(es)
|
2010-09-08 |
2020-04-17 |
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Receptores de antígenos quiméricos con una región bisagra optimizada
|
|
WO2012136231A1
(en)
|
2010-09-08 |
2012-10-11 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
|
|
CN106963947A
(zh)
|
2010-11-22 |
2017-07-21 |
伊纳特医药股份有限公司 |
Nk细胞调节治疗和用于治疗血液恶性疾病的方法
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US20120321666A1
(en)
|
2011-05-23 |
2012-12-20 |
Cooper Laurence J N |
T cell therapy for b cell lymphoma
|
|
WO2013040371A2
(en)
|
2011-09-16 |
2013-03-21 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
AU2011377617B2
(en)
|
2011-09-23 |
2018-03-08 |
Bluebird Bio, Inc. |
Improved gene therapy methods
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
CN103294374A
(zh)
|
2012-02-23 |
2013-09-11 |
中兴通讯股份有限公司 |
一种触摸屏解锁方法及装置
|
|
CN102637127B
(zh)
|
2012-02-24 |
2015-04-08 |
青岛海信电器股份有限公司 |
一种控制鼠标模块的方法及电子设备
|
|
PT3578201T
(pt)
|
2012-06-28 |
2023-05-10 |
Univ Of Central Florida Research Foundation Incorporated |
Métodos e composições para células assassinas naturais
|
|
WO2014011993A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Epitope spreading associated with car t-cells
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
CA2918608A1
(en)
|
2012-08-03 |
2014-02-06 |
Icahn School Of Medicine At Mount Sinai |
Biomarker associated with risk of melanoma reoccurrence
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
WO2014055413A2
(en)
|
2012-10-02 |
2014-04-10 |
Bloodcenter Research Foundation |
A method of providing cellular therapy using modified natural killer cells or t lymphocytes
|
|
KR102198058B1
(ko)
|
2012-10-02 |
2021-01-06 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
US20150329640A1
(en)
|
2012-12-20 |
2015-11-19 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
|
SG11201505858VA
(en)
|
2013-01-28 |
2015-09-29 |
St Jude Childrens Res Hospital |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
KR102332790B1
(ko)
|
2013-02-15 |
2021-12-01 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
KR102363191B1
(ko)
|
2013-02-26 |
2022-02-17 |
메모리얼 슬로안 케터링 캔서 센터 |
면역치료용 조성물 및 방법
|
|
CN103113470B
(zh)
|
2013-02-27 |
2015-04-22 |
四川大学 |
靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
|
|
WO2014138704A1
(en)
|
2013-03-07 |
2014-09-12 |
Baylor College Of Medicine |
Targeting cd138 in cancer
|
|
US20160024175A1
(en)
|
2013-03-10 |
2016-01-28 |
Baylor College Of Medicine |
Chemotherapy-resistant immune cells
|
|
CA2904265C
(en)
|
2013-03-15 |
2023-08-08 |
Victor D. FEDOROV |
Compositions and methods for immunotherapy
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CA2909701C
(en)
|
2013-04-17 |
2022-12-06 |
Baylor College Of Medicine |
Immunosuppressive tgf-.beta. signal converter
|
|
EP2997134B1
(en)
|
2013-05-14 |
2020-06-24 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
KR102301464B1
(ko)
|
2013-06-10 |
2021-09-14 |
다나-파버 캔서 인스티튜트 인크. |
종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
KR102308597B1
(ko)
|
2013-10-17 |
2021-10-01 |
내셔널 유니버시티 오브 싱가포르 |
다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
|
|
SG11201603228TA
(en)
|
2013-10-31 |
2016-05-30 |
Hutchinson Fred Cancer Res |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
EP3071222B1
(en)
|
2013-11-21 |
2020-10-21 |
UCL Business Ltd |
Cell
|
|
PT3083671T
(pt)
|
2013-12-20 |
2020-12-24 |
Hutchinson Fred Cancer Res |
Moléculas efetoras quiméricas etiquetadas e recetores destas
|
|
JP2017504601A
(ja)
|
2013-12-20 |
2017-02-09 |
セレクティスＣｅｌｌｅｃｔｉｓ |
免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
|
|
CN107074957B
(zh)
|
2014-01-13 |
2021-05-07 |
希望之城公司 |
在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
|
|
CN106414723A
(zh)
|
2014-02-10 |
2017-02-15 |
纳维基因股份有限公司 |
细胞调节纳米组合物及使用方法
|
|
MX369513B
(es)
|
2014-02-14 |
2019-11-11 |
Univ Texas |
Receptores de antígenos quiméricos y métodos de realización.
|
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
WO2015154012A1
(en)
|
2014-04-03 |
2015-10-08 |
Memorial Sloan-Kettering Cancer Center |
Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
|
|
EP3134432B1
(en)
|
2014-04-25 |
2019-12-25 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
US10479975B2
(en)
|
2014-06-06 |
2019-11-19 |
Bluebird Bio, Inc. |
Methods of making T cell compositions
|
|
CA2951355C
(en)
|
2014-06-18 |
2023-10-31 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Car-expressing nk-92 cells as cell therapeutic agents
|
|
KR20170032406A
(ko)
|
2014-07-15 |
2017-03-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료를 위한 조작된 세포
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
DK3189132T3
(da)
|
2014-09-04 |
2020-08-10 |
Stemcell Tech Inc |
Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
|
|
JP2017527310A
(ja)
|
2014-09-09 |
2017-09-21 |
ユーナム・セラピューティクスＵｎｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ |
キメラ受容体および免疫療法におけるその使用
|
|
KR102777371B1
(ko)
|
2014-09-15 |
2025-03-07 |
오스페달레 산 라파엘 에스.알.엘. |
키메라 항원 수용체
|
|
EP3193894A1
(en)
|
2014-09-16 |
2017-07-26 |
Fundación Pública Andaluza Progreso Y Salud |
Use of cord blood plasma to treat nk cell-mediated diseases and ifn- mediated diseases
|
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
BR112017008696A2
(pt)
|
2014-10-27 |
2017-12-26 |
Univ Central Florida Res Found Inc |
métodos e composições para células exterminadoras naturais
|
|
HUE050264T2
(hu)
|
2014-11-05 |
2020-11-30 |
Juno Therapeutics Inc |
Eljárások transzdukálásra és sejtfeldolgozásra
|
|
EP3215534B1
(en)
|
2014-11-05 |
2020-04-15 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
US20170333480A1
(en)
|
2014-11-05 |
2017-11-23 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
EP3018200A1
(en)
|
2014-11-07 |
2016-05-11 |
Fondazione Matilde Tettamanti e Menotti de Machi Onlus |
Improved method for the generation of genetically modified cells
|
|
CA2967222C
(en)
|
2014-11-12 |
2023-10-31 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
RU2017125531A
(ru)
|
2014-12-19 |
2019-01-21 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Химерные антигенные рецепторы и способы их применения
|
|
JP2018502115A
(ja)
|
2014-12-31 |
2018-01-25 |
アントフロゲネシス コーポレーション |
ナチュラルキラー細胞及びその使用
|
|
WO2016109668A1
(en)
|
2014-12-31 |
2016-07-07 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
US10377988B2
(en)
|
2015-01-23 |
2019-08-13 |
Musc Foundation For Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
|
MA41433A
(fr)
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
|
JP6849600B6
(ja)
|
2015-01-29 |
2021-06-30 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
キメラ抗原受容体、組成物及び方法
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
GB201501936D0
(en)
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
WO2016124765A1
(en)
|
2015-02-06 |
2016-08-11 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
PL3253865T3
(pl)
|
2015-02-06 |
2022-10-10 |
National University Of Singapore |
Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
|
|
GB201503742D0
(en)
|
2015-03-05 |
2015-04-22 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
SG10201908203SA
(en)
|
2015-03-05 |
2019-10-30 |
Hutchinson Fred Cancer Res |
Immunomodulatory Fusion Proteins And Uses Thereof
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
US9777064B2
(en)
|
2015-03-17 |
2017-10-03 |
Chimera Bioengineering, Inc. |
Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
|
|
EP3270960A4
(en)
|
2015-03-20 |
2018-08-08 |
Bluebird Bio, Inc. |
Vector formulations
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
WO2016154585A1
(en)
|
2015-03-26 |
2016-09-29 |
Charles Sentman |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
|
HK1250918A1
(zh)
|
2015-04-06 |
2019-01-18 |
Cytoimmune Therapeutics, Inc. |
用於胶质母细胞瘤的egfr导向的car疗法
|
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016172537A1
(en)
|
2015-04-23 |
2016-10-27 |
The Trustees Of The University Of Pennsylvania |
Compositions to disrupt protein kinase a anchoring and uses thereof
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507104D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
WO2016179684A1
(en)
|
2015-05-11 |
2016-11-17 |
University Health Network |
Method for expansion of double negative regulatory t cells
|
|
IL255888B2
(en)
|
2015-05-28 |
2023-03-01 |
Kite Pharma Inc |
Diagnostic methods for t-cell therapy
|
|
HK1246201A1
(zh)
|
2015-05-28 |
2018-09-07 |
Armo Biosciences, Inc. |
用於治疗癌症的聚乙二醇化白细胞介素-10
|
|
US20180161368A1
(en)
|
2015-05-29 |
2018-06-14 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
US11154572B2
(en)
|
2015-06-05 |
2021-10-26 |
Board Of Regents, The University Of Texas System |
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
|
|
JP2018517415A
(ja)
|
2015-06-10 |
2018-07-05 |
ナントクエスト インコーポレイテッド |
がんを処置するための改変ｎｋ−９２細胞
|
|
TW202444897A
(zh)
|
2015-06-25 |
2024-11-16 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
KR20180038447A
(ko)
|
2015-06-29 |
2018-04-16 |
더 존스 홉킨스 유니버시티 |
면역 체크포인트 키메라 수용체 치료법
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
CA2994412A1
(en)
|
2015-07-31 |
2017-02-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins targeting cd56 and uses thereof
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
EP3331912B1
(en)
|
2015-08-04 |
2024-05-01 |
Xyphos Biosciences Inc. |
Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
|
|
CN115960230A
(zh)
|
2015-08-07 |
2023-04-14 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
KR20180042361A
(ko)
|
2015-08-24 |
2018-04-25 |
셀렉티스 |
통합된 통제가능한 기능들을 가진 키메라 항원 수용체들
|
|
EP3138905A1
(en)
|
2015-09-04 |
2017-03-08 |
Miltenyi Biotec GmbH |
Method for natural killer cell expansion
|
|
WO2017058752A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
US20180291080A1
(en)
|
2015-09-28 |
2018-10-11 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
BR112018009129A2
(pt)
|
2015-11-04 |
2019-02-26 |
J. PRICEMAN Saul |
receptores de antígeno quimérico que visam her2
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
CN107109363A
(zh)
|
2015-11-09 |
2017-08-29 |
张明杰 |
增强对异常细胞杀伤力的方法和药物组合物
|
|
AU2016363025B2
(en)
|
2015-12-03 |
2021-04-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
|
JP6853514B2
(ja)
|
2015-12-27 |
2021-03-31 |
国立大学法人東海国立大学機構 |
炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
|
|
EP3405567A4
(en)
|
2016-01-20 |
2019-10-30 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
AU2017244108B2
(en)
|
2016-03-29 |
2021-03-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
CN105838677B
(zh)
|
2016-05-20 |
2019-07-02 |
杭州优善生物科技有限公司 |
一种高效扩增冷冻保存nk细胞的方法及其应用
|
|
AU2017279548B2
(en)
|
2016-06-08 |
2024-08-08 |
Precigen, Inc. |
CD33 specific chimeric antigen receptors
|
|
CN105985931A
(zh)
|
2016-06-21 |
2016-10-05 |
黑龙江天晴干细胞股份有限公司 |
一种nk细胞体外扩增组合物及nk细胞扩增方法
|
|
EP3487991B1
(en)
|
2016-07-25 |
2022-09-07 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing modified natural killer cells and methods of use
|
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
|
CN108148862B
(zh)
|
2016-12-05 |
2019-03-08 |
上海优卡迪生物医药科技有限公司 |
一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
|
|
KR20190098747A
(ko)
|
2016-12-05 |
2019-08-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 치료법을 위한 조작된 세포의 제조방법
|
|
EP3567049A4
(en)
|
2016-12-28 |
2020-08-26 |
Green Cross Lab Cell Corporation |
CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
SG11202000402PA
(en)
|
2017-08-10 |
2020-02-27 |
Nat Univ Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
CN109554348A
(zh)
|
2017-09-27 |
2019-04-02 |
亘喜生物科技（上海）有限公司 |
可诱导分泌抗cd47抗体的工程化免疫细胞
|
|
CA3079076A1
(en)
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
|
CN107827990B
(zh)
|
2017-10-30 |
2020-07-10 |
河北森朗生物科技有限公司 |
一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
|
|
JP2021502114A
(ja)
|
2017-11-10 |
2021-01-28 |
キネオ メディカル テクノロジー カンパニー リミテッド |
改変された免疫細胞およびその使用
|
|
WO2019127215A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
CN109971712B
(zh)
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
|
|
CN111712516A
(zh)
|
2018-02-09 |
2020-09-25 |
新加坡国立大学 |
粘附受体构建体及其在自然杀伤细胞免疫疗法中的用途
|
|
US12258381B2
(en)
|
2018-02-09 |
2025-03-25 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
IL317065A
(en)
|
2018-03-02 |
2025-01-01 |
Allogene Therapeutics Inc |
Chimeric inducible cytokine receptors
|
|
WO2019178259A2
(en)
|
2018-03-14 |
2019-09-19 |
Celledit Llc |
Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
|
|
CN112055717B
(zh)
|
2018-04-02 |
2024-04-26 |
新加坡国立大学 |
用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
US20210338727A1
(en)
|
2018-09-13 |
2021-11-04 |
Nkarta, Inc. |
Natural killer cell compositions and immunotherapy methods for treating tumors
|
|
CN111088231A
(zh)
|
2018-10-24 |
2020-05-01 |
艾生命序公司 |
Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
|
|
AU2019385873A1
(en)
|
2018-11-26 |
2021-06-03 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020247392A1
(en)
|
2019-06-04 |
2020-12-10 |
Nkarta, Inc. |
Combinations of engineered natural killer cells and engineered t cells for immunotherapy
|
|
CN114286683B
(zh)
|
2019-07-17 |
2024-10-01 |
新加坡国立大学 |
由免疫细胞合成和分泌的功能性结合物
|
|
CA3144724A1
(en)
|
2019-07-31 |
2021-02-04 |
James Barnaby Trager |
Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
|
|
JP2023512452A
(ja)
|
2020-01-13 |
2023-03-27 |
ンカルタ・インコーポレイテッド |
Ｂｃｍａ指向性細胞免疫療法組成物および方法
|
|
EP4165171A4
(en)
|
2020-06-12 |
2025-03-26 |
Nkarta, Inc. |
GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
|
|
WO2022051749A1
(en)
|
2020-09-02 |
2022-03-10 |
Nkarta, Inc. |
Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof
|
|
CA3254363A1
(en)
|
2022-03-07 |
2023-09-14 |
Nkarta, Inc. |
Multiplex gene-edited cells for CD70-led cancer immunotherapy
|